Biocon’s Oral Insulin Gains Momentum With JDRF Backing
Executive Summary
Biocon’s oral insulin program has received a boost with the US-based JDRF supporting plans to progress its drug candidate in type 1 diabetes. While the pullback of players like Novo Nordisk underscores the potential risks in the oral insulin space, JDRF says early results of Biocon’s candidate “warrant support” for further studies.
You may also be interested in...
ADA Meeting's Around The Corner: Five Things To Watch For
Among other debates at the American Diabetes Association annual meeting, clinicians will discuss the future of cardiovascular outcomes studies for diabetes drugs – whether they should maintain course or are due for an overhaul.
It’s Coming Home: ImmunoACT Advances Plans For Cut-Price CAR-T In India
ImmunoACT CEO Dr Rahul Purwar outlines progress made by the firm’s early-stage CAR-T therapy in India, which he believes can be available at a tenth of the price of current on-market treatments or around the cost range for bone marrow transplant. Laurus Labs, which holds about 27% in ImmunoACT, is expected to help shape the firm’s globalization plans.
What’s Next At Dr Reddy’s: Biologics CDMO, Cell And Gene Therapy Push
Indian firms are getting their act together in areas like cell and gene therapy, with Dr Reddy’s aiming big and readying a facility alongside an alliance with a Chinese firm for a CAR-T therapy. The company is also doubling down in contract development and manufacturing, with an eye on opportunities in biologics.